

## Product Data Sheet

Product Name: Prinomastat (AG3340)

Cat. No.: GC32951

### Chemical Properties

Cas. No. 192329-42-3

SMILES O=C([C@@H]1N(S(=O)(=O)C2=CC=C(OC3=CC=NC=C3)C=C2)=O)CCSC1(C)C)NO

Formula  $C_{18}H_{21}N_3O_5S_2$  M.Wt 423.51

Solubility Soluble in DMSO Storage Store at  $-20^{\circ}C$

General tips For obtaining a higher solubility, please warm the tube at  $37^{\circ}C$  and shake it in the ultrasonic bath for a while. Stock solution can be stored below  $-20^{\circ}C$  for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure

### Background

Prinomastat is an inhibitor of matrix metalloproteinase-2 (MMP-2), MMP-3, MMP-9, MMP-13, and MMP-14 ( $IC_{50}$ s = 0.05, 0.3, 0.26, 0.03, and 0.33 nM, respectively).<sup>1</sup> It is selective for these MMPs over MMP-1 and MMP-7 ( $IC_{50}$ s = 8.3 and 54 nM, respectively). Prinomastat (50 mg/kg) reduces tumor growth and inhibits the formation of lung metastases in a murine Lewis lung carcinoma model. It also reduces the incidence of kidney, but not brain, metastasis and tumor microvessel density in an NCI H460 lung cancer orthotopic mouse model when administered at a dose of 100 mg/kg.<sup>2</sup> Prinomastat reduces bronchoalveolar lavage fluid (BALF) levels of TNF- $\alpha$  and pulmonary edema in a rat model of ventilator-induced lung injury.<sup>3</sup>

1. Scatena, R. Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases Expert Opin. Investig. Drugs 9(9)2159-2165(2000) 2. Liu, J., Tsao, M.S., Pagura, M., et al. Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

**Product Data Sheet**

---

modelLung Cancer42(3)335-344(2003) 3.Foda, H.D., Rollo, E.E., Drews, M., et al.Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: Attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340)Am. J. Respir. Cell Mol. Biol.25(6)717-724(2001)

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**